诺思格 (301333)
R&G PharmaStudies Co., Ltd.
K-Line Chart
No K-line data available
Company NameNuoshi Ge (Beijing) Pharmaceutical Technology Co., Ltd.
Listing Date2022-08-02
Issue Price78.88RMB
Registered Capital9658.125610k RMB
Legal RepresentativeWU JIE
Registered AddressNo. 518, Chuangyi West Road, East District, Economic Development Zone, Tongzhou District, Beijing
IndustryMedical Services
Main BusinessClinical trial outsourcing service provider, offering comprehensive integrated services for the entire drug clinical R&D process to global pharmaceutical companies and research institutions.
Company ProfileNuoshi Ge (Beijing) Pharmaceutical Technology Co., Ltd. is one of China's leading and large-scale Clinical Research Organizations (CROs). Headquartered in Beijing, it has offices in Shanghai, Changsha, Guangzhou, Wuhan, Chengdu, Xi'an, Harbin, Nanjing, Shenyang, Tianjin, Changchun, Hangzhou, Hefei, and other provincial capital cities. It covers over 60 cities in China and 6 countries/regions in Asia, having collaborated with more than 200 institutions, over 450 hospitals, and more than 600 departments. To date, it has provided international-standard clinical research outsourcing services to over 260 domestic and international clients. Its business encompasses comprehensive services including new drug evaluation and consulting, regulatory affairs, clinical trial execution, data management and statistical analysis, medical affairs, and training.
Stock Details
1. Key Indicators
- Total Shares(W): 9658.13
- Circulating A-Shares(W): 5717.02
- Earnings Per Share(RMB): 1.0000
- Net Assets Per Share(RMB): 19.8894
- Operating Revenue(W RMB): 60737.04
- Total Profit(W RMB): 10981.49
- Net Profit Attributable to Parent(W RMB): 9556.68
- Net Profit Growth Rate(%): 13.21
- Weighted Return on Equity(%): 5.0800
- Operating Cash Flow Per Share(RMB): 0.3570
- Undistributed Profit Per Share(RMB): 7.9418
- Capital Reserve Per Share(RMB): 11.0296
2. Main Business
The main business covers:
- Providing comprehensive, integrated full-process clinical drug development services for global pharmaceutical companies and research institutions.
3. Company Basic Information
- Company Name: R and G PharmaStudies Co., Ltd.
- Listing Date: 2022-08-02
- Industry: Research and Experimental Development
- Address: 11th Floor, North Tower, Building B, Huatong Plaza, No.19 Chegongzhuang West Road, Haidian District, Beijing, China
- Website: www.rg-pharma.com
- Company Profile: The company, formerly known as R&G PharmaStudies (Beijing) Co., Ltd., was transformed into a foreign-invested joint-stock company in July 2015. It provides comprehensive, integrated full-process clinical drug development services for global pharmaceutical companies and research institutions.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Ningbo Kangyunfu Equity Investment Co., Ltd. | General Legal Person | 1152.00 | 20.15 |
| 2 | Ningbo Ruiguang Venture Capital Partnership (Limited Partnership) | General Legal Person | 684.00 | 11.96 |
| 3 | Harmony Growth Phase II (Yiwu) Investment Center (Limited Partnership) | General Legal Person | 333.25 | 5.83 |
| 4 | National Social Security Fund 413 Portfolio | Social Security Fund | 294.63 | 5.15 |
| 5 | National Social Security Fund 601 Portfolio | Social Security Fund | 172.03 | 3.01 |
| 6 | Noah Pioneer Mixed Securities Investment Fund Class A | Fund | 167.96 | 2.94 |
| 7 | Zhuhai Harmony Health Investment Fund (Limited Partnership) | General Legal Person | 149.65 | 2.62 |
| 8 | Ningbo Ruiming Equity Investment Co., Ltd. | General Legal Person | 115.20 | 2.02 |
| 9 | Shenzhen Capital Group Co., Ltd. | General Legal Person | 70.40 | 1.23 |
| 10 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 69.04 | 1.21 |
5. Concept Sectors
- Artificial Intelligence
- CXO Concept
- AIGC Concept
- Innovative Drugs
- AI Healthcare
- Margin Trading & Securities Lending
- Imminent Share Unlock
- High-Performance Stock
- Growth Enterprise Board Small Cap
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information